Macrophages as independent prognostic factors in small T1 breast cancers

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 141-148

  Carrio, Roberto ^a,e   Koru Sengul, Tulay ^b,e   Miao, Feng ^d,e   Glück, Stefan ^d,e   Lopez, Omar ^e   Selman, Yamil ^e   Alvarez, Consuelo ^c,e   Milikowski, Clara ^c,e   Gomez, Carmen ^c,e   Jorda, Merce ^c,e   Nadji, Mehrad ^c,e   Torroella Kouri, Marta ^a,b,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Microbiology and Immunology   (United States)

^c Departments of Epidemiology and Public Health and Pediatrics   (United States)

^d Departments of Medicine   (United States)

^e UNIVERSITY OF MIAMI   (United States)

Author keywords

Ethnicities; Macrophages; Prognostic factors; T1 small breast cancers

Indexed keywords

CD68 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LATINA; MACROPHAGE; MITOSIS INDEX; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MIDDLE AGED; NEOPLASM GRADING; PILOT PROJECTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84872909498     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2088     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Karlsson E, Danielsson A, Delle U, et al: Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet Cytogenet 172: 139-146, 2007.
3. Eng-Wong J and Isaacs C: Prediction of benefit from adjuvant treatment in patients with breast cancer. Clin Breast Cancer 10 (Suppl 1): E32-E37, 2010.
4. Oakman C, Bessi S, Zafarana E, et al: Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 11: 205, 2009.
5. Marchionni L, Wilson RF, Marinopoulos SS, et al: Impact of gene expression profiling tests on breast cancer outcomes. Evid Rep Technol Assess (Full Rep): 1-105, 2007.
6. Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8: R23, 2008.
7. Sica A, Larghi P, Mancino A, et al: Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349-355, 2008.
8. Pollard JW: Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84: 623-630, 2008.
9. Qian BZ, Li J, Zhang H, et al: CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225, 2011.
10. Sica A, Saccani A and Mantovani A: Tumor-associated macrophages: a molecular perspective. Int Immunopharmacol 2: 1045-1054, 2002.
11. Leek RD and Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7: 177-189, 2002.
12. Zhang BC, Gao J, Wang J, et al: Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 28: 1447-1452, 2011.
13. Zhang B, Yao G, Zhang Y, et al: M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (São Paulo) 66: 1879-1886, 2011.
14. Chen JJ, Lin YC, Yao PL, et al: Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953-964, 2005.
15. Mantovani A, Sica A, Allavena P, Garlanda C and Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70: 325-330, 2009.
16. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.
17. Fedewa SA, Edge SB, Stewart AK, et al: Race and ethnicity are associated with delays in breast cancer treatment (2003-2006). J Health Care Poor Underserved 22: 128-141, 2011.
18. Miranda PY, Tarraf W and Gonzalez HM: Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Res Treat 128: 535-542, 2011.
19. Miranda PY, Tarraf W, Gonzalez P, Johnson-Jennings M and Gonzalez HM: Breast cancer screening trends in the United States and ethnicity. Cancer Epidemiol Biomarkers Prev 21: 351-357, 2012.
20. McGuire WL, De La Garza M and Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37: 637-639, 1977.
21. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
22. Elston CW: The assessment of histological differentiation in breast cancer. Aust NZ J Surg 54: 11-15, 1984.
23. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
24. Berrang TS, Lesperance M, Truong PT, et al: Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer? Breast Cancer Res Treat 133: 695-702, 2012.
25. Arslan AA, Silvera D, Arju R, et al: Atypical ezrin localization as a marker of locally advanced breast cancer. Breast Cancer Res Treat 134: 981-988, 2012.
26. Mook S, Knauer M, Bueno-de-Mesquita JM, et al: Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 17: 1406-1413, 2010.
27. Reis-Filho JS and Pusztai L: Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378: 1812-1823, 2011.
28. Raam S, Gelman R, Cohen JL, et al: Estrogen receptor assay: interlaboratory and intralaboratory variations in the measurement of receptors using dextran-coated charcoal technique: a study sponsored by E. C. O. G. Eur J Cancer 17: 643-649, 1981.
29. Mahmoud SM, Lee AH, Paish EC, et al: Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol 65: 159-163, 2012.
30. Shabo I, Stal O, Olsson H, Dore S and Svanvik J: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer 123: 780-786, 2008.
31. Lau SK, Chu PG and Weiss LM: CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 122: 794-801, 2004.
32. Brown M, Tsodikov A, Bauer KR, Parise CA and Caggiano V: The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 112: 737-747, 2008.
33. Vona-Davis L and Rose DP: The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 18: 883-893, 2009.
34. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109: 1721-1728, 2007.
35. Thakkar JP and Mehta DG: A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative. Oncologist 16: 276-285, 2011.
36. Hugh J, Hanson J, Cheang MC, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27: 1168-1176, 2009.